OncoMethylome diagnostic news

OncoMethylome disclosed in its 1H10 report that it plans to shift its focus to commercial diagnostic and pharmacogenetics from cancer screening to improve cash flow. OncoMethylome will initially focus on developing stand-alone molecular diagnostics based on its DNA methylation technology. OncoMethylome plans to out-license its colorectal cancer blood-based screening test and related biomarkers and close its Netherlands facility by year end. ...